GhoshTSRampelliSJefferyIBSantoroANetoMCapriMet al
[39] Amirato, G.R., Borges, J.O., Marques, D.L., Santos, J.M.B., Santos, C.A.F., Andrade, M.S
Oral Semaglutide 25 mg: OASIS-4 Trial Orforglipron in Obesity: ATTAIN-1 Trial Orforglipron in Type 2 Diabetes: ACHIEVE-1 Trial Comparison With Rybelsus 14 mg Patient Case Variations Summary Table Key Takeaways Read More New NEJM Trials: Oral GLP-1 Therapies for Obesity and Diabetes Three new NEJM trials highlight the potential of oral GLP-1 therapies for obesity and diabetes
Now 36, she says her cholesterol and blood sugar levels have improved, and she's closer to her dream of traveling further afield from her native Minneapolis
The Role of Physician-Supervised Care in Weight Loss Understanding how the therapy works is only part of the picture